Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 477 participants.

Also called NCT01951638

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 477 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01951638
  • EudraCT 2013-002288-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01951638. Randomized; quadruple masking; primary purpose treatment. Start 2013-11-06 (actual); primary completion 2015-08-18 (actual). Results posted on 2021-02-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Condition
Heart Failure
Intervention (Drug)
Vericiguat (BAY1021189) (1.25 mg)
Intervention (Drug)
Vericiguat (BAY1021189) (5 mg)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01951638
Content hash
399bfe5cd6e2a2960b4937189c1f1b3215ca9750658d421e9fd259a503bdac41